Cost-effectiveness of antenatal anti-D prophylaxis.
This paper estimates the incremental cost-effectiveness of providing antenatal anti-D prophylaxis in varying dose sizes to either primigravidae or all Rh D negative women. It presents a model for calculating the net cost per 1000 'at risk' women based on the costs of anti-D prophylaxis and the future NHS costs avoided. Incremental cost-effectiveness is measured in terms of the net cost per Rh D-alloimmunization and the net cost per Rh HD loss prevented. Programmes for Rh D negative primigravidae are more cost-effective than the same dose protocol extended to all Rh D negative women. The 1 x 1250 iu programme is the most cost-effective option.
Vick
S
S
Department of Management and Social Sciences, Queen Margaret College, Edinburgh.
Cairns
J
J
Urbaniak
S
S
Whitfield
C
C
Raafat
A
A
D015331:Cohort Studies; D003362:Cost-Benefit Analysis / Q000379:methods / Q000706:statistics & numerical data; D004305:Dose-Response Relationship, Drug; D004899:Erythroblastosis, Fetal / Q000191:economics* / Q000517:prevention & control; D005260:Female; D005544:Forecasting; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006302:Health Services Research / Q000191:economics / Q000379:methods; D006801:Humans; D007231:Infant, Newborn; D018803:Models, Economic; D010298:Parity / Q000276:immunology; D011247:Pregnancy; D011295:Prenatal Care / Q000191:economics* / Q000379:methods; D019057:Quality-Adjusted Life Years; D012189:Retrospective Studies; D018029:Rho(D) Immune Globulin / Q000008:administration & dosage / Q000191:economics*; D012606:Scotland; D013222:State Medicine / Q000191:economics; D026712:Value of Life
D018029:Rho(D) Immune Globulin